Utility of Pharmacogenomic Testing in Patients With Gastrointestinal Disorders

Inclusion Criteria * Rome IV criteria for functional nausea and vomiting disorders (chronic nausea vomiting syndrome, cyclic vomiting syndrome), abdominal bloating/distention, dyspepsia, irritable bowel syndrome, chronic abdominal pain, functional diarrhea, or chronic constipation. * On 1 or more medications identified in Appendix 1 on a daily basis for at least six months. * Symptoms of moderate or severe severity on either of these 2 instruments: For IBS-SSS, use moderate (175-300) or severe (\> 300) IBS. For FD - Score ≥ 3 for any symptom on Nepean Dyspepsia Index. * No prior pharmacogenomics assessment. * Willingness to adjust medications based upon results of PGX testing. * Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures. * Patients must have the ability to complete questionnaires by themselves or with assistance. Exclusion Criteria: * Patients who decline to be evaluated by a mental health professional during their evaluation. * Rumination syndrome, cannabinoid hyperemesis syndrome, patients with a significant GI disease process (e.g., intestinal pseudo-obstruction, severe gastroparesis, megacolon) which, in the opinion of the investigator, is likely irreversible. * Patients who, in the opinion of the investigator, are likely to undergo another major therapeutic intervention during the next 6 months (e.g., surgery or pelvic floor retraining by biofeedback therapy). However, other changes (e.g., medications) will not preclude participation in the study. * Patients with any of the following per history, and review of medical record prior to study entry: any psychotic disorders, bipolar disorders, or major cognitive disorders; any active substance use disorders, other than tobacco; currently active suicidal ideation; current treatment with electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS); discharge from a psychiatric inpatient hospital or intensive psychiatric outpatient program within 6 weeks prior to GI consultation. * Patients who are unwilling or cannot, for any reason, adjust their medications.